Patent Oppositions in metabolic drugs industry

Explore the competitive field of metabolic drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in metabolic drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Feb 12, 2026
CompanyTotal Oppositions
NOVARTIS182
BOEHRINGER INGELHEIM111
NOVO NORDISK77
AMGEN44
NUTRICIA41
BRISTOL MYERS SQUIBB39
CELGENE37
F HOFFMANN LA ROCHE35
NESTLE34
PFIZER31

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the metabolic drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the metabolic drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Feb 12, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Manufacture Of A Crystalline Pharmaceutical ProductORIONJan 9, 2026ADALVO
Manufacture Of A Crystalline Pharmaceutical ProductORIONJan 8, 2026HAMPTON KNOWLES
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression Innpm1MEMORIAL SLOAN KETTERING CANCER CENTERJan 7, 2026STRAWMAN
Formulation For Inhibiting Formation Of 5-Ht 2B Agonists And Methods Of Using SameZOGENIXJan 6, 2026ALFRED E TIEFENBACHER
Crystal Form Of Ozanimod, Crystal Form Of Hydrochloride Thereof, And Preparation Method ThereforCRYSTAL PHARMACEUTICAL SUZHOUJan 2, 2026BRAND MURRAY FULLER
Chimeric Antigen Receptors Targeting B-Cell Maturation AntigenTHE UNITED STATES OF AMERICADec 31, 2025BOULT WADE TENNANT
Crystal Form Of Ozanimod, Crystal Form Of Hydrochloride Thereof, And Preparation Method ThereforCRYSTAL PHARMACEUTICAL SUZHOUDec 30, 2025ADALVO
Treatment Of Breast Cancer Using Combination Therapies Comprising Gdc-9545 And Gdc-0077GENENTECHDec 29, 2025BOTTI & FERRARI
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKDec 24, 2025POLPHARMA
Crystal Form Of Ozanimod, Crystal Form Of Hydrochloride Thereof, And Preparation Method ThereforCRYSTAL PHARMACEUTICAL SUZHOUDec 23, 2025SANDOZ

To stay ahead in the competitive metabolic drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the metabolic drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Feb 12, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Aug 18, 2021Formulations Of EnzalutamideASTELLAS PHARMA12
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIM11
Mar 2, 2022Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNA10
Sep 14, 2022Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIM10